Clarivate Plc Stock Price, News & Analysis

Clarivate Plc (NYSE:CLVT) has announced a partnership with OhioLINK and SearchOhio to develop a new unified library resource sharing experience across Ohio. The collaboration aims to integrate OhioLINK and SearchOhio's existing INN-Reach platforms into a single consortial solution, expected to be implemented by mid-2025.

The new system will provide a seamless user experience for accessing library materials from 45 public library systems and 87 institutions statewide. It will offer an intuitive interface for patrons to discover resources and explore new content, potentially improving learning outcomes. This initiative builds on OhioLINK's 30-year history of leveraging technology for educational support and SearchOhio's commitment to enhancing public library services.

Clarivate Plc (NYSE: CLVT), a global provider of transformative intelligence, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, before the market opens. The company will release a press release and earnings supplement with financial information on its investor website. Additionally, Clarivate will host a conference call and webcast at 9:00 AM Eastern Time on the same day to review the results. The webcast will be open to all interested parties and may include forward-looking statements.

Clarivate Plc (NYSE:CLVT) has released its annual G20 scorecard, analyzing research and innovation trends across G20 members. The 2024 report, compiled by the Institute for Scientific Information, includes interactive data visualizations and, for the first time, data for the European Union and African Union. Key findings highlight:

- African Union's high collaboration rate and focus on SDGs 1 and 5
- European Union as the largest contributor of papers
- Germany's above-average citation impact and open access publishing
- India's increasing international collaboration
- Mainland China's shifting collaboration patterns
- South Korea's rising collaborations with China and India
- UK's high citation impact and strong international collaboration
- US's strong patent citation impact in various fields

The scorecard aims to provide a comprehensive view of the global research landscape, informing policymakers and research institutions for strategic decision-making.

Clarivate launched a report on the Unitary Patent Court's (UPC) first year of litigation activity. The analysis, based on Darts-ip data, showed consistent monthly infringement filings averaging ten per month. The number of UPC decisions rose 155% in the second half compared to the first half. German divisions dominated infringement cases, with Munich accounting for 37.7%. Six of the top ten plaintiffs were U.S.-based, and major representative firms handled 71.3% of cases. Electrical engineering led in infringement cases with 39.8%, while instruments led in revocation cases at 36%. The ICT industry saw 38.5% of patents asserted before the UPC.

Clarivate has released its MedTech Trends to Watch 2024 report, announcing key trends and challenges in the MedTech sector. Highlighting economic uncertainty, regulatory changes, and supply chain issues, the report also identifies opportunities in AI integration, ambulatory surgical centers, and advancements in technologies like pulsed-field ablation and surgical robotics. The shift from inpatient to outpatient settings for procedures and the impact of GLP-1 receptor agonists are significant. Macro trends such as an aging population and increased healthcare access are driving further innovation and investment. Regulatory changes in Mainland China and supply chain resilience are important areas of focus. The report is based on insights from over 40 analysts covering 80 markets in more than 50 countries.

Clarivate (NYSE: CLVT) released a Global Research Report highlighting the rapid growth in digital health research and innovation. The report, developed by the Institute for Scientific Information (ISI) and the Clarivate Center for IP and Innovation Research, analyzes data from multiple Clarivate portfolios. It reveals a 70-fold increase in digital health academic publications from 2012 to 2022 and identifies nearly 140,000 patent inventions from 2013 to 2022. Key players in the field include organizations like Snap, AstraZeneca, and the Chinese Academy of Sciences. The advancements in AI and digital technologies, such as mobile apps and telemedicine, are driving this growth, improving healthcare delivery and reducing costs. The study builds on initial findings presented at Digital Health 2024 held at Stanford University.

Clarivate Plc (NYSE: CLVT) unveiled the IP Collaboration Hub™ at the 2024 Clarivate Ignite conference in San Diego. This new solution integrates with Clarivate's IP management systems (IPMS), providing a central hub for collaboration with local agents globally. It aims to streamline IP filing and prosecution by automating and standardizing communication management. The hub mitigates risks associated with email reliance and improves efficiency by automatically docketing communications in the IPMS. This launch aligns with Clarivate's strategy to enhance IP lifecycle support and maintain leadership in patent maintenance and IP management software.

Clarivate, a leading provider of transformative intelligence, has released the 2024 update to the Journal Citation Reports (JCR). This update features a comprehensive ranking of high-quality journals, incorporating the Emerging Sources Citation Index (ESCI) for a more unified category view. The JCR now includes 21,800 journals, with 544 receiving their Journal Impact Factor (JIF) for the first time.

Significant enhancements include integrated rankings across subject categories, eliminating separate JIF rankings for journals indexed in multiple editions. This change unifies the rankings of journals across fields such as psychiatry. The update aims to support research integrity and level the global playing field by valuing all trustworthy journals uniformly.

The 2024 release recognizes scholarly journals from 113 countries across 254 categories, offering a more complete user experience with enriched data, metrics, and analysis.

Clarivate has released its 2024 Companies to Watch report, spotlighting seven innovators in antibody-drug conjugates (ADCs) set to revolutionize cancer treatment. The report highlights companies like Adcendo, Araris Biotech, GO Therapeutics, Heidelberg Pharma, Pheon Therapeutics, Tallac Therapeutics, and Tubulis, which are advancing ADC technology to provide targeted cancer therapies with fewer side effects. Major pharmaceutical companies are keen on integrating ADCs into their portfolios. The number of ADCs on the market has surged in the past five years, reflecting their growing impact. Despite historical challenges in ADC development, new approaches are overcoming these barriers, positioning ADCs as a cornerstone in modern oncology.